CK19和BCL-2以及MYC基因mRNA联合检测对乳腺癌诊断的临床应用研究  

Clinical application of CK19,BCL-2 and MYC gene in the diagnosis of breast cancer by combined detection

作　　者：邓君[1] 黄文芳[1] 饶绍琴[1] 传良敏[1] 洪华[1] 

机构地区：[1]四川省医学科学院四川省人民医院检验科,四川成都610072

出　　处：《现代肿瘤医学》2013年第4期762-764,共3页Journal of Modern Oncology

基　　金：四川省杰出青年基金资助项目(编号:2007-5-345)

摘　　要：目的:探讨核内原癌基因(nuclear oncogene,MYC)和B细胞淋巴瘤/白血病-2基因(B cell lympho-ma/leukemia 2 gene,BCL-2)与细胞角蛋白19(nuclear oncogene,CK19)基因表达水平在乳腺癌诊断和治疗监测中的应用。方法:建立荧光定量聚合酶链反应(FQ-PCR)法,并以GAPDH为内对照测定34名健康女性体检者、55例良性乳腺疾病患者和91例乳腺癌患者外周血中MYC,BCL-2和CK19的表达量。结果:MYC,BCL-2和CK19表达水平与GAPDH的比值在乳腺癌组显著高于健康女性体检者和良性乳腺疾病患者(P<0.05),它们在正常对照组和良性乳腺疾病组间差异无统计学意义(P>0.05),3组GAPDH差异无统计学意义(P>0.05);MYC,BCL-2与CK19联合检测的灵敏度高于单个基因的检测。结论:FQ-PCR技术可以快速定量检测MYC,BCL-2和CK19 mRNA,三者联合检测可有效提高对乳腺癌诊断的灵敏度。Objective：To evaluate the clinical application of MYC, BCL -2 and CK19 gene in the diagnosis of breast cancer by combined detection. Methods： MYC, BCL -2 and CK19 in the samples of 34 health women,55 patients with benign breast disease and 91 patients with breast cancer were detected by FQ - PCR. β2 - microglobin was used as internal control, Results： MYC, BCL -2 and CK19/β2 -microglobin in breast cancer group were higher than those in health women and patients with benign breast disease groups （ P 〈 0.05 ）. There were no significant difference in MYC, BCL- 2 and CK19/β2 -mieroglobin between normal controls and benign breast disease group（ P 〉 0.05 ）. There were no difference in β2 - mieroglobin among three groups （ P 〉 0.05 ）. The sensitivity of MYC, BCL - 2 and CK19 gene express by combined detection was higher than that of single gene detection. Conclusion： FQ -PCR is a rapid method for quantitating MYC, BCL- 2 and CK19. The combined detection can improve the sensitivity of diagnosis in breast cancer.

关 键 词：荧光定量聚合酶链反应 MYC BCL-2 CK19 乳腺癌 

分 类 号：R737.9[医药卫生—肿瘤]